AACR 2025 China ADC Achievements OverviewAACRExplore key highlights from AACR 2025, where Chinese biotech firms showcased breakthroughs in ADC therapies, including dual-target, dual-payload innovations and promising clinical outcomes in solid tumor treatments.
PD-(L)1 Resistance HopePD-1Explore how LRRC15+ CAFs contribute to PD-1 resistance, the role of LRRC15 in tumor immunity, and emerging therapies targeting LRRC15 and PD-1 to improve cancer immunotherapy outcomes.
Innovative Drugs: The Changing TimesFDARecent advancements in ADC therapies are reshaping cancer treatment. AstraZeneca and Gilead's breakthroughs in first-line therapies for breast and TNBC cancers mark a new era in innovative drug development.
Hengrui Pharmaceutical ADC Drug OverviewHengruiHengrui has emerged as a leading force in ADC drug development, with a deep pipeline of 12 ADC drugs in clinical trials. Its proprietary HRMAP? platform and strategic innovations in targeting toxins and drug conjugation offer promising breakthroughs.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
